

**Table EU Approved biosimilars by molecule May 2020**

(not available in all EU-countries) (status June 04, 2020; 57 products)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Amsparity, Halimatoz, Hefiya, Hulio, Hyrimoz, Idacio, Imraldi
bevacizumab	Avastin	MVasi, Zirabev
Enoxaparine	Clexane	Inhixa
Epoetine alfa	Eprex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi, Nepexto
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin Aspart	Novo Rapid	Insulin Aspart Sanofi (pos.opinion.)
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Cegfila, Fulphila, Grasustek, Pelgraz, Pelmeg, Udenyca, Ziextenzo
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Ruxience, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac (pos.opinion)

Source: EMA website

[https://www.ema.europa.eu/medicines/field\\_ema\\_web\\_categories%253Aname\\_field/Human/ema\\_group\\_types/ema\\_medicine/field\\_ema\\_med\\_status/authorised36/ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar/search\\_api\\_aggregation\\_ema\\_medicine\\_types/field\\_ema\\_med\\_biosimilar](https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar)

Accessed: June4, 2020

For a comparison with US/FDA (January 2020) see:

<https://www.biosimilarsip.com/2020/01/28/u-s-biosimilar-launches-accelerate-with-five-launches-in-q4-2019-and-early-2020/>

FDA approved biosimilars (status June 3, 2020)

<https://biosimilarsrr.com/us-biosimilar-filings/>

15 Biosimilar-products in the licensing pipeline at EMA (Status: 4/6/2020).

Adalimumab (1x); Bevacizumab (6x), insulin aspart (1x), Insulin Human (rDNA) 1x; pegfilgrastim (1x), teriparatide (3x), trastuzumab (2x).